Cell cycle deregulation influences many cancers.1 Although in the current standard of care (SOC), clinicopathological factors and events at the molecular level largely determine diagnostic, therapeutic, and patient management pathways in cancer, the patient-to-patient variability in therapy response, as well as in cancer remission and recurrence, can be further influenced by the degree of deregulation of key cell cycle events.